MEDICATION |
Controlling Insulin Is Good For Diabetes - And Breast Cancer?
Doctors have long encouraged patients with diabetes to exercise regularly to help control their insulin levels and to maintain a healthy weight. Now, breast oncologists at Dana-Farber Cancer Institute in Boston are studying the relationship between exercise, weight, and insulin levels and the risk of breast cancer recurrence. |
Controversial Diabetes Med Doesn't Slow Plaque
The controversial diabetes pill Avandia failed to significantly slow plaque buildup in heart arteries compared with an older drug, though there were some hopeful signs in a new study reported Wednesday. |
| Diabetes Study In Foot Ulcer Patients
Foot ulcers are known to be associated with heart disease and the experts realised that the appearance of a foot ulcer pointed to arterial damage elsewhere in the body. They decided to give every patient, being treated after 2001, medicines to actively target heart disease even if they had no history of cardiovascular illness to protect them from future episodes. |
|
| FDA Approves Rapid-Acting Insulin Apidra(R) For Treatment Of Children With Diabetes
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus. The approval of Apidra(R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro, in 572 children and adolescents (4 years and older) with type 1 diabetes. |
|
| Inhaled Insulin Passes FDA Review
An advisory panel for the Food and Drug Administration (FDA) approved the first-ever inhaled form of insulin today, providing a new option for people with diabetes who have never quite taken to insulin shots. The expert panel voted 7-2 to approve the new insulin device, known as Exubera, for patients with either the type 1 or type 2 form of the disease. The FDA must still formally approve Exubera, but it usually follows the advice of its committees. |
|
| Personalized Medicine For Monogenic Diabetes
In the last two years a team at the University of Chicago Medical Center has been able to wean more than 30 children who appeared to have type-1 diabetes off of insulin. This is not a miracle cure but a clever application of modern genetics and the tweaking of ion channels. |
|
| Pharmacists Help Patients Understand And Better Manage Their Diabetes
The American Pharmacists Association (APhA) wants consumers, particularly those with diabetes, to talk to their pharmacist during November's Diabetes Awareness Month. According to the American Diabetes Association, there are 23.6 million people in the United States, or 8% of the population, who have diabetes, an increase of 13.5 percent from 2005. As the prevalence of diabetes rises at an alarming rate, pharmacists are playing a critical role in helping patients manage the disease. |
|
| Researcher Uncovers Important Piece Of Puzzle Of How Insulin Works
A PhD student at Sydney's Garvan Institute of Medical Research has uncovered an important piece in the puzzle of how insulin works, a problem that has plagued researchers for more than 50 years. This finding brings us one step closer to explaining exactly how insulin prompts fat and muscle cells to absorb glucose. |
|
| Scientists From Granada Find A Potential Treatment To Prevent Diabetes And Obesity
A molecule called interleukin-6 has opened new doors for the creation of new drugs against obesity and diabetes. These are the conclusions of an international project which has had the participation of researchers from Vitagenes, a company which forms part of the Campus program promoted by the University of Granada (UGR) and situated in the Technological Park of Health Sciences (PTS). |
|
| Smartinsulin, Insulin That Knows When It's Needed!
SmartInsulin is the idea of Dr Todd Zion, the CEO of SmartCells, Inc., a biotechnology company based in the USA. The concept is simple - deliver insulin in such a way that it is only released into the blood stream when it is needed. The new approach involves using a plant-derived protein that can bind and release insulin in response to glucose levels. |
|
| The Future Of Human Insulin: Tailored And Oral
Insulin therapy has evolved in the last century from purified bovine or porcine insulin to biosynthetic human insulin to recombinant human insulin and eventually to recombinant insulin analogs as the 3rd generation of human insulin. Tailored insulin analogs as the 4ht generation insulin and other long-acting insulins for injection with drug delivery solutions aim at optimized pharmacokinetic profiles in order to avoid hyper- and hypoglycemic episodes. |
|
| Tougher U.S. Rules For Diabetes Drugs Debated
Drug makers should do more testing to see if proposed new diabetes medicines may damage patients' hearts, a prominent cardiologist told a U.S. advisory panel on Tuesday. Other experts warned that tough standards could stifle development of new treatments by requiring longer and more expensive clinical trials. The U.S. market for the top-selling diabetes medicines now exceeds $6 billion. |
|
| Trends In The Diabetes Drug Pipeline 2008
Diabetes is one of the most challenging health problems of the 21st century. It is estimated that today around 194 million people suffer from diabetes (more than 85 % have type 2 diabetes). Forecasts predict that the prevalence of diabetes will rise to almost 333 million by the year 2025. The 2007 market of major branded diabetes drugs was more than US$ 18 bln with a variety product categories (proteins, peptides, small molecules). The pipeline exists of more than 50 different approaches. |
|
| Well Known Drug Might Overcome Obstacles To Pancreatic Islet Transplantation
Researchers from Ben-Gurion University of the Negev (BGU) in Beer-Sheva, Israel have demonstrated that treating diabetic animals with alpha-1-antitrypsin (AAT) following an islet transplantation procedure eliminates the inflammation that causes islet transplants to fail. (PNAS Article #08-07627: "Alpha-1-Antitrypsin Monotherapy Induces Immune Tolerance during Islet Allograft Transplantation in Mice") |
|